‘Metabolomic analysis’ of patients’ blood using gas chromatography-mass spectrometry shows high sensitivity and specificity for pancreatic cancer.
Despite significant toxicity, the FOLFIRINOX chemotherapy regimen is associated with clinical responses among patients with locally advanced pancreatic ductal adenocarcinoma, according to research presented at SSO 2013.
Multivariate nomogram models predict patients’ risks of progression of adenomas to high-grade dysplasia/carcinoma in situ and invasive carcinoma in main and branch-duct intraductal papillary mucinous neoplasms of the pancreas, according to research presented at SSO 2013.
Use of rigid, elastic system cuts detection of microfocal cancer; ups detection of high-grade cancer
Research results presented at the 2013 Gastrointestinal Cancers Symposium have the potential to offer patients with pancreatic ductal adenocarcinoma better treatment options and outcomes.
In an age of impressive and ever-improving medical technology, the basic physical exam findings of many diseases have taken a back seat to more expensive diagnostic and laboratory tests.
Weekly nanoparticle albumin-bound (nab)-paclitaxel plus gemcitabine significantly improved survival in patients with metastatic adenocarcinoma of the pancreas compared with gemcitabine alone, results of a global phase 3 trial reported in advance of being presented during the 10th annual Gastrointestinal Cancers Symposium on January 25th in San Francisco, CA.
Patients with pancreatic cancer may benefit from pharmacogenomic (PGx) modeling that profiles response to chemotherapy, as well as from treatment with the agent S-1.
Pancreatic fistulas and other postoperative complications are associated with more than double the risk of delayed gastric emptying after conventional or pyloric-preserving pancreaticoduodenectomy for pancreatic cancer.